

The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

As a precautionary measure, Lupin Pharmaceuticals, Inc. is initiating a recall of five lots of **Liraglutide Injection 6 mg/mL (2s Pack)** and six lots of **Liraglutide Injection 6 mg/mL (3s Pack)** at the **Retail** level. These drug product lots are being recalled due to a single market complaint. The reported complaint was identified as a white thread-like structure in the cartridge. Based on the Health Hazard Assessment conducted for the reported complaint, no adverse events are expected from the consumption of these products. In a worst-case scenario, the product may have the potential to cause acute, localized inflammatory reactions.

The recalled lots were distributed nationwide to wholesalers, distributors, supermarkets and mail order pharmacies between October 2025 and April 2026.

#### **Liraglutide Injection 6 mg/mL (2s Pack)**

<b>Strength</b>	<b>Lot</b>	<b>Expiry</b>	<b>NDC</b>	<b>Description</b>
6 mg/mL	WB00097	Jul. 2027	70748-346-02	Clear colorless solution free from visible particulate matter in glass cartridge assembled in blue colored pen injector device with blue button.
	WB00094	Jul. 2027		
	WB00088	Jul. 2027		
	WB00103	Oct. 2027		
	WC00016	Dec. 2027		

**Liraglutide Injection 6 mg/mL (3s Pack)**

<b>Strength</b>	<b>Lot</b>	<b>Expiry</b>	<b>NDC</b>	<b>Description</b>
6 mg/mL	WB00098	Jul. 2027	70748-346-03	Clear colorless solution free from visible particulate matter in glass cartridge assembled in blue colored pen injector device with blue button.